GCF and Saliva Levels of IL-36α in Periodontal Disease

Ordu University

Status: Completed

Conditions: Saliva; Cytokine; Periodontal Diseases; Gingival Crevicular Fluid

Treatments: Diagnostic Test: Collection of fluid samples

Study type: Interventional

Funder types: Other

Identifiers

NCT07497828

2023\314

Details and patient eligibility

About

Interleukin-36 (IL-36), recently identified and members of the IL-1 family, have been reported to be important regulators of host defense against pathogens in the oral mucosa. The aim of this study was to investigate the levels of IL-36 alpha (α) in saliva and gingival crevicular fluid (GCF) of patients with periodontitis, gingivitis and periodontally healthy individuals and to compare these levels with clinical parameters.

Full description

Interleukin-36 (IL-36), recently identified and members of the IL-1 family, have been reported to be important regulators of host defense against pathogens in the oral mucosa. The aim of this study was to investigate the levels of IL-36 alpha (α) in saliva and gingival crevicular fluid (GCF) of patients with periodontitis, gingivitis and periodontally healthy individuals and to compare these levels with clinical parameters.

Materials and Methods: A total of 80 systemically healthy, non-smokers aged between 25 and 55 including 20 periodontally healthy individuals, 20 individuals with gingivitis, 20 individuals with Stage III Grade B periodontitis, and 20 individuals with Stage III Grade C periodontitis were involved in our study. Clinical parameters, including plaque index (PI), gingival index (GI), probing pocket depth (PPD), clinical attachment level (CAL), and bleeding on probing (BOP), were recorded. GCF and unstimulated saliva samples were collected from all participants. IL-36α levels were quantified using enzyme-linked immunosorbent assay (ELISA).

Enrollment: 80 patients

Sex: All

Ages: 18 to 55 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• at least 20 teeth
• older than 18 years

Exclusion criteria

• any systemic disease
• pregnant or lactating
• history of radiotherapy or chemotherapy
• used antibiotics or any anti-inflammatory medication
• smokers
• had undergone periodontal treatment within the previous 6 months

Trial design

Primary purpose: Diagnostic

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Single Blind

---

80 participants in 4 patient groups

Control group

Other group

Description:

Periodontally and systemically healthy individuals

Treatment:

Diagnostic Test: Collection of fluid samples

Gingivitis

Other group

Description:

Systemically healthy and patients with Gingivitis

Treatment:

Diagnostic Test: Collection of fluid samples

Stage III Grade B Periodontitis

Other group

Description:

systemically healthy and patients with Stage III Grade B periodontitis

Treatment:

Diagnostic Test: Collection of fluid samples

Stage III Grade C Periodontitis

Other group

Description:

systemically healthy and patients with Stage III Grade C periodontitis

Treatment:

Diagnostic Test: Collection of fluid samples